Last week at ARVO 2024, Elva Adán-Castro presented a compelling scientific poster showing the efficacy of VIAN-c4551 eyedrop on different disease models of diabetic retinopathy. Our team is at the forefront of innovation and is dedicated to advancing eye care solutions that make a tangible difference in patients' lives. Together, we're shaping the future of eye care! #diabetes #diabeticretinopathy #DME #ARVO2024
VIAN Therapeutics
Biotechnology Research
San Francisco , CA 148 followers
Protecting sight with a simple eye drop.
About us
VIAN Therapeutics is a visionary virtual pharma startup at the forefront of combating microvascular retinal diseases. Focused on conditions like diabetic retinopathy and age-related macular degeneration, we're pioneering a novel solution: VIAN-c4551, a groundbreaking cyclic peptide drug delivered via convenient eyedrop administration. By swiftly stabilizing retinal blood vessels, our non-invasive approach aims to halt vision deterioration earlier than traditional methods (e.g., intraocular injections). With millions affected, VIAN Therapeutics aims to redefine ocular care, offering hope for clearer sight and a brighter future of retinal health.
- Website
-
www.viantx.com
External link for VIAN Therapeutics
- Industry
- Biotechnology Research
- Company size
- 1 employee
- Headquarters
- San Francisco , CA
- Type
- Privately Held
- Founded
- 2023
- Specialties
- angiogenesis, peptides, vasopermeability, diabetic retinopathy, diabetic macular edema, AMD, macular degeneration, oncology, angiogenesis inhibitors, antiangiogenic, and eye drop
Locations
-
Primary
Get directions
San Francisco , CA, US
Employees at VIAN Therapeutics
-
Qianying Zuo
Ph.D. in Biomedical and Molecular Nutrition
-
Philipp N. Sander, PhD
Investor @ IndieBio/SOSV / ChemBio PhD from Scripps ResearchAre you building a startup in human or planetary health? Let's chat!
-
Prem Patel
Doctor of Pharmacy Candidate (PharmD) Class of 2025
-
JP Robles
VIAN Therapeutics CEO | Improving antiangiogenic therapy in convenience and efficacy
Updates
-
Last week at ARVO 2024, María Magdalena Zamora Corona presented a groundbreaking scientific poster! She explored the high penetrance into the eye and the longevity of our therapeutic candidate. Her presentation sparked insightful discussions among attendees. We are proud of our team's commitment to advancing vision health! #ARVO2024 #VIAN #EyeCareInnovation
-
-
VIAN Therapeutics has been selected to participate in the Spring 2024 FAST Cohort of the California Life Sciences (CLS). At VIAN Therapeutics, we are committed to protecting vision for patients grappling with retinal diseases through simple and convenient treatments. Being part of CALS FAST not only validates our commitment but also signifies a significant milestone in our journey toward fulfilling this crucial mission. Thank you for your support and belief in our vision. Stay tuned for updates as we embark on this exciting chapter!
-
-
Exciting News! Our CEO, JP Robles, will attend the 4th Annual Wet AMD & Diabetic Eye Disease Drug Development Summit in Boston, MA, from March 19 to 21. Joining industry experts, he aims to transform treatments for retinal vascular diseases, improving patient outcomes. VIAN Therapeutics remains committed to leading innovation in eye treatment. #EyeHealth #DrugDevelopment #VIANTherapeutics #Summit2024
-
-
VIAN-c4551 is a safe molecule. It is not inflammatory, apoptotic, or fibrinolytic. It safely inhibits VEGF and other proangiogenic molecules to stop angiogenesis and vascular permeability.
Our team is thrilled to announce the publication of our latest scientific paper, revealing groundbreaking insights into the molecular complexities of vasoinhibin. The discovery of TWO distinct functional motifs within the same molecule is a significant stride forward, providing valuable insights into structure-function relationships and future drug development. Notably, our findings showcase that the HGR-containing vasoinhibin analog stands out by lacking inflammatory, apoptotic, and fibrinolytic components. Suggesting a safer profile for potential clinical applications. https://lnkd.in/g5wtFZWY
-